[Renal toxicities of targeted therapies in oncology].
This article reviews the renal toxicity associated with targeted anticancer therapies directed against Epidermal growth factor receptor, Human epidermal growth factor-2, B-rapidly accelerated fibrosarcoma, Mitogen-activated protein kinase, Anaplastic lymphoma kinase, Programmed cell death-1/programmed cell death ligand-1, Cytotoxic T lymphocyte antigen-4 and Vascular endothelial growth factor/receptor. The early diagnosis and management of these renal adverse events is essential for the clinician who cares for such patients.
PMID: 31818703 [PubMed - as supplied by publisher]
Source: Nephrologie and Therapeutique - Category: Urology & Nephrology Authors: Izzedine H Tags: Nephrol Ther Source Type: research
More News: Cancer & Oncology | Chemotherapy | Fibrosarcoma | Lymphoma | Science | Toxicology | Urology & Nephrology